arrow
D

Dipenkumar Modi

wayne state university
H指数:18
被引数:1,231

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Phase II Study of Posttransplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis After HLA-Mismatched Unrelated Donor Reduced Intensity Transplantation: Results From the ACCESS Trial Expansion Cohort

HLA错配无关供者减低强度移植后移植抗宿主病预防的术后环磷酰胺方案II期研究:ACCESS试验扩展队列结果

2026-09-010
OAAI
Outcomes after 7/8 and <7/8 mismatched unrelated donor PBSC transplantation with PTCy: results from the ACCESS trial

7/8和<7/8位点不合无关供者外周血干细胞移植后结局:ACCESS试验结果

2026-08-210
OA
Infection Burden in Mismatched Unrelated Donor Hematopoietic Cell Transplantation: Results from the ACCESS Trial

不匹配无关供者造血细胞移植中的感染负担:ACCESS试验的结果

2026-07-160
OA
Comparison of Outcomes With Novel Versus Traditional Chemotherapy Regimens for Relapsed and Refractory Classical Hodgkin Lymphoma

比较新型与传统化疗方案对复发性和难治性经典霍奇金淋巴瘤的疗效

2026-05-010
PRE
A Phase I Study of Blinatumomab/Lenalidomide in Relapsed/Refractory B cell Lymphoma; Toxicity, Efficacy and Correlative Analysis

Blinatumomab/Lenalidomide治疗复发/难治性B细胞淋巴瘤的I期研究;毒性、疗效及相关性分析

2025-11-120
OAAI
Matched Unrelated vs Haploidentical Donor Hematopoietic Cell Transplantation Using Post-Transplant Cyclophosphamide

匹配无关供者与半合子相合供者造血细胞移植使用移植后环磷酰胺

2025-10-080
OAAI
Real-World Outcomes of Infections Following Tisagenlecleucel in Patients with B-Cell ALL: A CIBMTR Analysis

tisagenleucel治疗后B-Cell ALL患者感染的实时世界结局:一项CIBMTR分析

2025-08-050
OAAI
Chimeric antigen receptor T-cell therapy for high-grade B-cell lymphoma NOS

嵌合抗原受体T细胞疗法治疗高级别B细胞淋巴瘤NOS

2025-07-220
PRE
Infection after CD19 chimeric antigen receptor T-cell therapy for large B-cell lymphoma: real-world analysis from CIBMTR

CD19嵌合抗原受体T细胞疗法治疗大B细胞淋巴瘤后的感染:CIBMTR的真实世界分析

2025-05-300
OAAI
CD19-directed CART therapy for T-cell/histiocyte-rich large B-cell lymphoma
2024-10-100
OAAI
Chimeric antigen receptor T-cell infusion for large B-cell lymphoma in complete remission: a center for international blood and marrow transplant research analysis
LEUKEMIA
IF13.4
2024-05-150
PRE
Mosunetuzumab with polatuzumab vedotin in relapsed or refractory aggressive large B cell lymphoma: a phase 1b/2 trial
2023-12-1018
OAAI
Allogeneic hematopoietic cell transplantation for blastic plasmacytoid dendritic cell neoplasm: a CIBMTR analysis
2023-11-177
OAAI
Effect of cumulative dose of brentuximab vedotin maintenance in relapsed/refractory classical Hodgkin lymphoma after autologous stem cell transplant: an analysis of real-world outcomes
2023-04-276
OAAI
Impact of pre-transplant induction and consolidation cycles on AML allogeneic transplant outcomes: a CIBMTR analysis in 3113AML patients (oct, 10.1038/s41375-022-01738-3, 2022)
LEUKEMIA
IF13.4
2023-03-220
OA
Impact of pre-transplant induction and consolidation cycles on AML allogeneic transplant outcomes: a CIBMTR analysis in 3113 AML patients
LEUKEMIA
IF13.4
2022-10-3011
OA
Association of Chronic Graft-versus-Host Disease with Late Effects following Allogeneic Hematopoietic Cell Transplantation for Children with Hematologic Malignancy

慢性移植物抗宿主病与异基因造血干细胞移植治疗儿童血液系统恶性肿瘤的晚期效应

2022-10-019
OAAI
Allogeneic transplant and CAR-T therapy after autologous transplant failure in DLBCL: a noncomparative cohort analysis
2022-01-1827
OAAI